# US 2012/0251510 A1 · Agents for promoting tissue regeneration by recruiting bone marrow mesenchymal stem cells and/or pluripotent stem cells into blood

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251510 A1
- Document ID: US20120251510A1
- Status: Published application
- Kind: A1
- Application number: 13/503,329
- Filed: 2010-10-28
- Published: 2012-10-04
- Earliest claimed: 2009-10-28
- Assignees: Stemrim Inc.; Osaka University
- Inventors: Katsuto Tamai; Yasufumi Kaneda; Takehiko Yamazaki; Takenao Chino; Kotaro Saga; Mayumi Endo
- Web page: https://patentgrep.com/patent/US20120251510A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/47: from mammals
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

It was revealed that the intravenous administration of HMGB-1 and S100A8 promoted the healing of skin ulcer by recruiting bone marrow-derived cells to the site of skin ulcer. Furthermore, when HMGB-1 was intravenously administered to cerebral infarction model mice after creation of cerebral infarction, bone marrow-derived cells expressing nerve cell markers were detected in their brain. A marked cerebral infarct-reducing effect was observed in mice intravenously administered with HMGB-1 as compared to the control. The post-cerebral infarction survival rate was increased in the intravenous HMGB-1 administration group. The involvement of bone marrow pluripotent stem cells in the process of bone fracture healing was assessed using mice, and the result demonstrated that bone marrow-derived cells distant from the damaged site migrated to the bone fracture site to repair the damaged tissue.

## Claims

### Claim 1

A tissue regeneration-promoting agent, comprising any one of:
(a) an HMGB1 protein;
(b) a cell that secretes an HMGB1 protein;
(c) a vector into which a DNA encoding an HMGB1 protein is inserted;
(d) an HMGB2 protein;
(e) a cell that secretes an HMGB2 protein;
(f) a vector into which a DNA encoding an HMGB2 protein is inserted;
(g) an HMGB3 protein:
(h) a cell that secretes an HMGB3 protein;
(i) a vector into which a DNA encoding an HMGB3 protein is inserted;
(j) an S100A8 protein;
(k) a cell that secretes an S100A8 protein;
(l) a vector into which a DNA encoding an S100A8 protein is inserted;
(m) an S100A9 protein;
(n) a cell that secretes an S100A9 protein;
(o) a vector into which a DNA encoding an S100A9 protein is inserted;
(p) a cell or tissue extract; and
(q) a heparin-binding fraction of a cell or tissue extract;
wherein the agent is administered to a tissue other than a tissue in need of regeneration.

### Claim 2 (depends on 1)

The agent of claim 1, which is administered parenterally.

### Claim 3 (depends on 2)

The agent of claim 2, which is administered by injection.

### Claim 4 (depends on 1)

The agent of claim 1, which is administered intravascularly, intramuscularly, subcutaneously, intradermally, or intraperitoneally.

### Claim 5 (depends on 1)

The agent according to claim 1, wherein the cell or tissue extract is produced by a method comprising the step of immersing a cell or tissue in a solvent.

### Claim 6 (depends on 1)

The agent according to claim 1, wherein the heparin-binding fraction of a cell or tissue extract is produced by a method comprising the steps of:
(a) immersing a cell or tissue in a solvent;
(b) contacting immobilized heparin with the extract prepared in step (a); and
(c) eluting a heparin-binding fraction from the immobilized heparin.

### Claim 7 (depends on 1)

The agent according to claim 1 for use in promoting the regeneration of a nerve, bone, or skin tissue.

### Claim 8

A method for promoting tissue regeneration, which comprises the step of administering an effective amount of a composition to a tissue other than a tissue in need of regeneration, wherein the composition comprises any one of:
(a) an HMGB1 protein;
(b) a cell that secretes an HMGB1 protein;
(c) a vector into which a DNA encoding an HMGB1 protein is inserted;
(d) an HMGB2 protein;
(e) a cell that secretes an HMGB2 protein;
(f) a vector into which a DNA encoding an HMGB2 protein is inserted;
(g) an HMGB3 protein;
(h) a cell that secretes an HMGB3 protein;
(i) a vector into which a DNA encoding an HMGB3 protein is inserted;
(j) an S100A8 protein;
(k) a cell that secretes an S100A8 protein;
(l) a vector into which a DNA encoding an S100A8 protein is inserted;
(m) an S100A9 protein;
(n) a cell that secretes an S100A9 protein;
(o) a vector into which a DNA encoding an S100A9 protein is inserted;
(p) a cell or tissue extract; and
(q) a heparin-binding fraction of at cell or tissue extract.

### Claim 9 (depends on 8)

The method of claim 8, wherein the administration is parenteral administration.

### Claim 10 (depends on 9)

The method of claim 9, wherein the administration is injection.

### Claim 11 (depends on 8)

The method of claim 8, wherein the administration is intravascular, intramuscular, subcutaneous, intradermal, or intraperitoneal administration.

### Claim 12 (depends on 8)

The method according to claim 8, which promotes the regeneration of a nerve, bone, or skin tissue.
